Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Acumen Pharmaceuticals, Inc. - Common Stock (NQ: ABOS ) 1.890 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 109 Open 1.890 Bid (Size) 1.880 (2) Ask (Size) 1.890 (12) Prev. Close 1.890 Today's Range 1.890 - 1.890 52wk Range 1.700 - 5.090 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference November 26, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights November 12, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Performance YTD -55.32% -55.32% 1 Month -14.09% -14.09% 3 Month -22.22% -22.22% 6 Month -19.92% -19.92% 1 Year -50.78% -50.78% More News Read More Earnings Scheduled For November 12, 2024 November 12, 2024 Via Benzinga Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference November 11, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals Earnings Preview November 11, 2024 Via Benzinga Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference November 06, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality November 06, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024 November 05, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference October 31, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference October 23, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference September 30, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease September 26, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024 September 25, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference September 03, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q2 2024 August 13, 2024 Via InvestorPlace Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights August 13, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024 August 06, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease July 29, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024 July 28, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024 July 11, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Trading SMID Biotech Stocks In A Volatile Market July 01, 2024 Via Talk Markets ABOS Stock Earnings: Acumen Pharmaceuticals Beats EPS for Q1 2024 May 14, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's Pre-Market Session May 14, 2024 Via Benzinga Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights May 14, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference May 13, 2024 From Acumen Pharmaceuticals, Inc. Via GlobeNewswire Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
